Brain Tumor Center Lenox Hill

(212) 434-3900

130 E. 77th Street, 3 Black Hall
New York, New York 10075

About us

The Lenox Hill Brain Tumor Center offers comprehensive care for brain and spinal cord tumors in adults and children. Our experts utilize state-of-the-art surgical and non-surgical techniques to treat tumors. In addition to our pursuit of evidence-based medicine, the Brain Tumor Center emphasizes treatment of the whole patient and respect for the role of family in a patients care plan.

We offer the best in clinical care from diagnosis to treatment and follow-up. Our patients come from around the world to seek care from our internationally renowned experts.

The research arm of the Lenox Hill Brain Tumor Center is the Laboratory for Brain Tumor Biology and Therapy at the Feinstein Institute for Medical Research. The lab draws experts from multiple disciplines to participate in cutting edge research into brain and spinal cord tumors.

Our neuroscientists use discoveries in the lab to create new treatments for patients through a robust clinical trial program. Our doctors run Brain Tumor Biotech Center at The Feinstein Institute for Medical Research, which is the only biotech center in the world dedicated to accelerating treatments for patients with brain tumors.

Brain Tumor Center at Lenox Hill Hospital

At Lenox Hill Neurosurgery, our team of neurosurgeons, nurse practitioners, and ENT specialists diagnose and treat complex brain tumors. Our world renown physicians are leaders in the treatment of these conditions and work diligently with researchers to develop new treatments.

Clinical expertise

The Lenox Hill Brain Tumor Center provides a comprehensive program for the treatment of brain and spinal cord tumors. Our center works closely with the Laboratory for Brain Tumor Biology and Therapy, and the Brain Tumor Biotech Center at The Feinstein Institute for Medical Research to offer cutting edge diagnosis and treatment.

Our neurosurgeons utilize surgical and non-surgical techniques to treat tumors. We have state-of-the-art equipment such as image guided systems for precise surgical navigation and radiotherapy for painless, non-surgical treatment.

Our multidisciplinary team specializes in treating all types of brain tumors, including:

Primary and Metastatic Brain Tumors

  • Glioblastoma
  • Anaplastic astrocytoma
  • Gliomas
  • Ependymoma
  • Low-grade astrocytoma
  • Oligodendroglioma
  • Mixed oligoastrocytomas
  • Pilocytic astrocytoma
  • Medulloblastoma
  • Brainstem glioma
  • Meningiomas
  • Lymphoma
  • All brain metastasis including breast, lung, prostate, colon, melanoma metastasis and all others

Skull Base Tumors

  • Acoustic neuroma
  • Pituitary adenomas
  • Meningiomas
  • Chordomas
  • Chondrosarcomas
  • Glomus tumors
  • Craniopharyngioma
  • Metastatic tumors to the skull base
  • Squamous cell carcinoma of the head and neck
  • Esthesioneuroblastoma
  • Neuroendocrine carcinoma
  • Pineal region tumors including pinealblastoma, pinealcytoma
  • Lymphoma

Spinal cord tumors

  • Neurofibroma
  • Spinal metatastasis
  • Meningiomas
  • Chordomas
  • Chondrosarcomas
  • Schwannoma
  • Neurogangliomas
  • Metastatic tumors to the spinal cord
  • Myxopapillary ependymoma

Our physicians

John Andrew Boockvar, MD

  • Vice Chair, Department of Neurosurgery,
    Lenox Hill Hospital
  • Director, Brain Tumor and Pituitary/ Neuroendocrine Center,
    Lenox Hill Hospital & Manhattan Eye, Ear and Throat Hospital
  • Investigator, Laboratory for Brain Tumor Biology,
    The Feinstein Institute for Medical Research
  • Professor, Neurosurgery and Otolaryngology/Head and Neck Surgery,
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Jason A. Ellis, MD

  • Neurosurgeon,
    Lenox Hill Hospital
  • Assistant Professor, Neurosurgery ,
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

David Langer, MD

  • Chair, Department of Neurosurgery,
    Lenox Hill Hospital
  • Director,
    Moyamoya Center
  • Professor, Neurosurgery and Radiology,
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Rafael Alexander Ortiz, MD

  • Chief, Neuro-Endovascular Surgery and Interventional Neuroradiology,
    Lenox Hill Hospital
  • Associate Professor, Neurosurgery, Neurology and Radiology,
    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Heustein Lu Sy, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

David Barrett Weintraub, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Peter David Costantino, MD

  • Chairman of Otolaryngology - Head and Neck Surgery, Lenox Hill Hospital
  • Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Richard Braunstein, MD

  • Executive Director,
    Manhattan Eye, Ear & Throat Hospital
  • Vice President, Ophthalmology Services,
    Northwell Health
  • Professor, Ophthalmology,
    Hofstra Northwell School of Medicine
  • view full profile

Alexis Matthew Demopoulos, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Dennis Harry Kraus, MD

  • Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Jane Ari Lee, MD

Jed Michael Pollack, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Bidyut Kumar Pramanik, MD

  • Chief - Neuroradiology of Radiology, Lenox Hill Hospital
  • Associate Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Samuel Joseph Wahl, MD

  • Chairman - Approved by the Jan 14 Med Board of Pathology, Lenox Hill Hospital
  • Chairman-Credentials Committee - Approved by the Dec 10, 2013 Med Board of Pathology, Lenox Hill Hospital
  • view full profile

Todd Arthur Anderson, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Anuj Goenka, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Dana Shani, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Christopher G. Filippi, MD

  • Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Jamie Roberts Mitchell, MD

  • Attending Neuro-ophthalmologist,
    Manhattan Eye, Ear & Throat Hospital and Lenox Hill Hospital
  • view full profile

Rosamaria Ruggieri, PhD

  • Assistant Investigator,
    The Feinstein Institute for Medical Research
  • Assistant Professor, Department of Molecular Medicine and Department of Neurosurgery ,
    Hofstra Northwell School of Medicine
  • view full profile

Marc Symons, PhD

  • Investigator,
    The Feinstein Institute for Medical Research
  • Co-Director,
    Brain Tumor Biotech Center, The Feinstein Institute for Medical Research
  • Professor, Department of Molecular Medicine and Department of Neurosurgery ,
    Hofstra Northwell School of Medicine
  • view full profile

Sewit Teckie, MD

  • Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • view full profile

Clinical Professionals

Sherese Fralin, MSN, FNP

  • Research Nurse Practictioner, Department of Neurosurgery,
    Lenox Hill Hospital
  • view full profile

Tamika Wong, MPH

  • Clinical Research Manager, Department of Neurosurgery,
    Lenox Hill Hospital
  • view full profile

Ashley Ray MS, FNP-BC

  • Nurse Practitioner, Department of Neurosurgery,
    Lenox Hill Hospital
  • view full profile

Research

The research arm of the Lenox Hill Brain Tumor Center is the Laboratory for Brain Tumor Biology and Therapy at Feinstein Institute for Medical Research. The lab draws experts from multiple disciplines to participate in cutting edge research into brain and spinal cord tumors.

Our neuroscientists use discoveries in the lab to create new treatments for patients through a robust clinical trial program. Our doctors run the Brain Tumor Biotech Center at The Feinstein Institute for Medical Research, which is the only biotech center in the world dedicated to accelerating treatments for patients with brain tumors.
 

Clinical trials

Our patients have access to clinical studies offering novel, state-of the art therapies developed by our own physicians, as well as those that are done in collaboration with other sites. Ongoing trials include the following:
 

Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/neu Positive Breast Cancer 
PI: John Boockvar, MD

The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into your artery for the treatment of your brain metastasis(es) from HER2/neu positive breast cancer. This study will try to determine the best tolerated single dosage of trastuzumab administered into arteries by gradually increasing the dosage given to participants as the study progresses. Early participants will receive a dosage of 1 mg/kg. As more participants enroll into the study, this single dosage will be increased at designated levels up to 8 mg/kg, if it’s determined to be safe to increase. Trastuzumab is a type of antibody, which is a protein used by the body’s immune system to fight against pathogens such as bacteria and viruses. This antibody binds to cell receptors known as the HER2/neu tyrosine kinase receptor. These receptors are expressed in certain cancer subtypes such as breast cancer. By blocking signaling through this HER2/neu receptor, trastuzumab can slow down or stop the over-expression of the HER2/neu protein. Over-expression of HER2/neu has been shown to play a role in the development and progression of certain types of breast cancer. Therefore, by slowing down or stopping the expression of HER2/neu, we hope to slow down or stop the growth of your metastasis(es) and increase the responsiveness to therapy.

Using genomic analysis to guide individualized treatment in glioblastoma multiforme (GBM). The purpose of this study is to assess whether the use of genomics can help identify patient specific treatment choices in cancer. In order to test this, we plan to use genomic sequencing technology to identify patient specific mutations in glioblastoma multiforme (GBM) as compared to normal cells of the blood from the same patient to identify mutations. Further analysis will identify potential treatment targets and whether there are any drugs that could be used for these particular mutations. Follow up clinical data will be assessed to see if this individualized method of choosing treatment options can improve clinical outcomes in patients with GBM.
 

Phase I Trial of Super-Selective Intra-Arterial Infusion of Cetuximab (ERBITUX) with or without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck 
PI: John Boockvar, MD

This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC). Cetuximab has recently emerged as a promising biological agent in the management of HNSCC. It is an epidermal growth factor receptor (EGFR) inhibitor which increases the radiosensitivity of tumors to radiotherapy (RT), and has been proven to be effective. A large body of evidence supports the theoretical attractiveness of intra-arterial chemotherapy, related to the first pass of the drug through the tumor bed and to the possibility of increasing the doses of the chemotherapeutic agent, thus minimizing systemic toxic side effects. Theoretically, a higher dose of Cetuximab saturating the tumor tissue’s EGFR receptor will increase its responsiveness with or without concurrent radiation therapy.
 

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I clinical research trial will test the hypothesis that Temozolomide can be safely used by Superselective Intraarterial Cerebral Infusion (SIACI) up to a dose of 250mg/m2 to ultimately enhance survival of patients with newly diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma. Data suggests that Temozolomide is active in newly diagnosed GBM but that current response rates can be improved, and toxicity with systemic delivery could be avoided with selective delivery techniques such as SIACI.
 

Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
PI: John Boockvar, MD

This phase I/II clinical research trial will test the hypothesis that repeated dosing of of intra-arterial Bevacizumab at 15 mg/kg can be safely administered to enhance survival of subjects with newly diagnosed Glioblastoma multiforme while they receive standard of care. We expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for newly diagnosed malignant glioma, and may alter the way these drugs are delivered to our patients in the future.
 

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
PI: John Boockvar, MD

A recent study showed that IV Bevacizumab (Avastin) treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both, in some patients with vestibular schwannoma who were at risk for complete hearing loss or brainstem compression from growing VS. Because of these promising results in preliminary studies, and because of our significant experience with the safety of intraarterial chemotherapy, this novel study will offer a safe treatment for patients with VS. This is the only center in the United States where this trial is being offered.
 

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

Superselective Intraarterial Cerebral Infusion (SIACI) is a technique that can effectively increase the concentration of drug delivered to the brain while sparing the body of systemic side effects. One currently used drug called, Cetuximab (Erbitux) has been shown to be active in human brain tumors but its actual CNS penetration is unknown. This phase I clinical research trial will test the hypothesis that Cetuximab can be safely used by direct intraarterial infusion up to a dose of 250mg/m2 to ultimately enhance survival of patients with relapsed/refractory GBM/AA. This study will allow investigators to determine the the toxicity profile and maximum tolerated dose (MTD) of SIACI Cetuximab. The investigators expect that this study will provide important information regarding the utility of SIACI Cetuximab therapy for malignant gliomas, and may alter the way these drugs are delivered to the investigators patients in the near future.
 

Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I/II clinical research trial will test the hypothesis that repeated direct intraarterial infusion Bevacizumab (15mg/kg) can be safely administered to enhance survival of patients with relapsed/refractory Glioblastoma Multiforme and Anaplastic Astrocytoma. The current standard of care for recurring GBM is for patients to receive Bevacizumab (Avastin) intravenously (IV) at 10mg/kg every two weeks until their tumor grows more than 25%. This study will help investigators determine if IV therapy with Bevacizumab should be combined with repeated selected intra-arterial Bevacizumab to improve progression free and overall survival.
 

Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) Plus Carboplatin (Paraplatin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I/II clinical research trial is an extension of our Phase I IA Avastin trial in that we seek to test the hypothesis that repeated dosing of intraarterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma. Additionally we will investigate whether the combination with Carboplatin will further improve the treatment response. We will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.
 

Phase I/II Trial Of Repeated Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I/II clinical research trial will test the hypothesis that repeated dosing of intra-arterial Cetuximab is safe and effective in the treatment of recurrent malignant glioma. We will also determine if IV therapy with Cetuximab should be combined with repeated selected intra-arterial Cetuximab to improve progression free and overall survival.

Lenox Hill Neurosurgery

Brain Tumor Biotech Summit 2017 Pictures

Click here to see pictures from our Brain Tumor Biotech Summit.

Experimental drug treatment offers hope to man with brain cancer

CBSNews.com features Dr. Boockvar’s novel clinical trials for malignant brain tumor.

Our centers

The Feinstein Institute for Medical Research

The researchers at the world-renowned Feinstein Institute for Medical Research are continually making advances in medicine.

130 E. 77th Street , 3 Black Hall
New York, New York 10075
View on Google Maps
View on Google Maps